Table 1.
Summary of characteristics of the 6 models studied.
| Line | Construct | Specific name |
CAG repeatsa (mean/range) |
Full name (vendor catalog number) |
Background (vendor) |
Refs. |
|---|---|---|---|---|---|---|
| R6/2 | Transgenic: human exon 1 under control of human HD promoter sequences |
R6/2 | 136 (128–142) CAG | B6CBATg (HD exon 1) 62Gpb/3J (Jax Stock No. 006494) |
CBAB6F1 (Jax) | (Mangiarini et al., 1997) |
| R6/2B | 260 (254–2276) CAG | Not commercially available | C57BL/6J (Jax) | NA | ||
| HdhQ111 | Knock-in: chimeric human/mouse exon 1 construct under control of mouse HD promoter |
HdhQ111 | 106 (97–114) CAG |
Htttm5Mem/J (Jax Stock No. 003456) |
CD1 (CRL)b | (Wheeler et al., 2000) |
| BACHD | Transgenic: full-length genomic construct under control of human HD promoter gene |
BACHD | 97–98 (CAG-CAA) | Not commercially available | FVB/NJ (Jax) | (Gray et al., 2008) |
| YAC128 | Transgenic: full-length genomic construct under control of human HD promoter |
YAC128 | 100 and 126 CAGs | FVB-Tg(YAC128)53Hay/J (Jax Stock No. 004938) |
FVB/NCrl (CRL)b | (Slow et al., 2003b) |
| YAC128B | 100 and 126 CAGs | Not commercially available | C57BL/6J (Jax) | (Van Raamsdonk et al., 2007) |
Note. Jax: Jackson Laboratories. CRL: Charles River Laboratories. NA=Not available, new line.
a
CAG repeat length correspond to the cohorts used in these studies.
b
Note that original background strain and current supplier differ, thus controls should be obtained from original vendor or backcrossing should be ensured.